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Abstract
Neonatal tumors encompass a group of heterogeneous neoplasms that demonstrate ana-
tomic locations, behavior patterns, histologic features, and treatment responses that are 
distinct from neoplasms found in older children. The majority of neonatal tumors are 
benign, with malignant lesions accounting for only 2% of childhood cancers. However, 
histologically benign tumors can lead to detrimental effects on the fetus and newborn 
due to their size and location in relation to vital structures. An understanding of the 
incidence, appearance, and typical locations of neonatal tumors can provide important 
diagnostic information and guide treatment decisions. Although surgical intervention 
is the mainstay of therapy for many neonatal tumors, it is important to recognize that 
some lesions will regress spontaneously, whereas others may respond to noninvasive 
treatment modalities. In this chapter, we explore the epidemiology of neonatal tumors 
and provide a location-based classification schema to aid in diagnosis. A summary of 
the presentation, diagnosis, and management of the most common neonatal tumors is 
provided as well.
Keywords: neonatal tumors, sacrococcygeal teratoma, neuroblastoma, infantile hepatic 
hemangioma, mesenchymal hamartoma, ovarian cyst, cervical lymphatic malformation, 
rhabdomyosarcoma, congenital mesoblastic nephroma
1. Introduction
Neonatal tumors encompass a group of heterogeneous neoplasms that are diagnosed prena-
tally or within the first 30 days of life. Neonatal tumors demonstrate anatomic locations, behav-
ior patterns, histologic features, and treatment responses that are distinct from neoplasms 
found in older children [1]. The preponderance of information regarding the epidemiology of 
neonatal tumors is provided through the experience of single institutions. The true incidence 
of these lesions is unknown, as studies do not always account for pregnancies with a prena-
tally diagnosed mass that end in stillbirth, miscarriage, or early termination of pregnancy.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Most solid neoplasms identified in neonates are benign [2]. The incidence of a malignant 
tumor is 1 in every 12,500–27,500 live births, accounting for 2% of all childhood cancers [1]. 
Distinguishing between benign and malignant neoplasms can prove to be challenging in this 
group of patients. The features of a tumor that denote malignancy in adults, such as high 
nuclear-cytoplasmic ratio, high mitotic rate, and anaplasia, may be present in benign lesions 
in children and neonates [3]. Neonatal tumors are also unique in that they arise from embry-
onic and immature tissue as a result of intrinsic dysfunction of cellular growth and prolifera-
tion [3, 4]. As opposed to adult tumors, environmental exposures are believed to play little 
to no role in tumorigenesis [4]. Some malignant lesions have minimal potential for invasion 
or metastasis, while histologically benign lesions can be lethal due to their size and location.
Although less than 10% of childhood cancers arise in the setting of a cancer predisposition 
syndrome, any neonatal tumor should raise concern for this possibility [5]. The presence of 
associated congenital anomalies, multifocal or bilateral disease, and cancer in close relatives 
is suggestive of an underlying cancer predisposition syndrome [6]. Several specific types of 
tumors, including retinoblastoma, adrenocortical carcinoma, pleuropulmonary blastoma, 
hepatoblastoma, and Wilms’ tumor, show a strong association with a cancer predisposition 
syndrome [5]. Since the presence of genetically derived lesions can have implications for these 
children and their family members, genetic counseling and testing should be offered.
2. Diagnosis
A thorough history and physical examination are paramount in the evaluation of a newborn. 
However, many anomalies can be detected prior to birth. The ability to diagnose neoplasms in 
utero has evolved significantly with improvement in imaging modalities. Fetal ultrasonogra-
phy, magnetic resonance imaging (MRI), and echocardiography offer physicians the opportu-
nity to diagnose a variety of congenital diseases in the prenatal period [7–9]. Ultrasonography 
is a critical component of the prenatal obstetric evaluation and is currently the standard of 
care. Prenatal ultrasound provides vital information regarding gestational age, number of 
fetuses, fetal health, and the presence of congenital anomalies [9]. Ultrasound and MRI are 
preferred because they avoid the damaging effects of ionizing radiation.
For decades, ultrasonography has been the principal imaging modality for prenatal diagnosis 
of fetal anomalies [10]. The benefits of ultrasound are numerous, including wide availability, 
low cost, noninvasiveness, and the ability, to provide real-time evaluation of the fetus. One 
shortcoming of ultrasound is that results are operator dependent and can vary with the experi-
ence and expertise of the examiner [11]. In a systematic review of ultrasound for fetal assess-
ment in early pregnancy, Bricker et al. [12] determined the overall sensitivity for detection of 
fetal anomalies to be 44.7%. However, the sensitivities of the included studies showed great 
variability, ranging from 15 to 85.3%. In addition to operator experience, gestational age, anom-
aly type, and equipment quality impact the accuracy of screening prenatal ultrasound [12].
In the past two decades, magnetic resonance imaging (MRI) has become increasingly uti-
lized as an adjunct to ultrasound in the evaluation of fetal and neonatal anomalies [8, 10, 13]. 
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One driving force behind this phenomenon is the development of ultrafast MRI, which limits 
fetal motion artifact and does not require maternal-fetal sedation [11]. The greatest utility of 
MRI appears to occur in cases where sonographic findings are equivocal or further diagnos-
tic information is desired [11, 14, 15]. MRI is also particularly useful in illustrating anatomic 
relationships between neoplasms and adjacent structures, characterizing intracranial and soft 
tissue lesions, in cases of oligohydramnios and in cases of maternal obesity [11, 14, 15].
In the most recent Guidelines for Diagnostic Imaging in Pregnancy and Lactation, the 
American College of Obstetricians and Gynecologists states that there is no evidence of harm 
from tissue heating, acoustic damage, or teratogenesis when using MRI in pregnancy [16]. 
However, one issue that merits discussion is the use of gadolinium contrast dye to enhance 
fetal imaging. In practice, gadolinium is administered as a gadolinium-chelate molecule that is 
water-soluble and can cross the placenta into fetal circulation. Following filtration and excre-
tion by the fetal kidneys, these molecules can accumulate in amniotic fluid with the ability to 
release potentially toxic gadolinium ions [17]. Although the effect of free gadolinium ions on 
the fetus is unknown, the current recommendation is to abstain from the routine use of MRI 
contrast agents unless the benefits can be shown to clearly outweigh this theoretical risk [17].
The diagnosis of a neonatal tumor has a profound emotional impact on a family and raises 
questions about accuracy of diagnosis, prognosis, treatment options, and long-term outcomes 
[18]. While technological improvements in imaging modalities have led to better sensitivity in 
diagnosing congenital anomalies, the false-positive rate is far from negligible [19]. Care should 
be taken in making definitive statements about diagnosis and prognosis on prenatal imaging as 
normal anatomic variants can have the appearance of a neoplastic process and some lesions will 
regress spontaneously. Conversely, sonographic findings of polyhydramnios, fetal hydrops, 
hepatosplenomegaly, and placentomegaly should raise suspicion for an undiagnosed tumor.
Finally, having diagnostic imaging that points to anomalies will allow the care team to have 
prenatal discussions and do important planning. Depending on all tests done, the parents 
should be offered possible diagnoses, complications, and outcomes. However, one needs to 
be guarded with prognostication, and consideration for termination of the pregnancy must 
be very carefully made including all knowns and unknowns. Assuming that the plans are for 
delivery, early diagnosis will allow for planning around the delivery; the location of the birth-
ing center (closer to home vs. in a maternal-neonatal center), the means of birth (vaginal vs. 
Cesarean section vs. ex utero intrapartum treatment (EXIT)), the personnel required for the 
birth aside from those needed to care for the mother (neonatologist, pediatric anesthesiolo-
gist, pediatric otolaryngologist, pediatric general surgeon, pediatric cardiothoracic surgeon), 
and logistics with regard to coordination of the team including diagnostic and operative 
services.
3. Anatomic considerations/locations
Neonatal tumors represent a varied group of neoplasms that are discovered in multiple locations 
throughout the body (Figure 1). The diversity observed is not surprising since these lesions arise 
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from abnormalities in fetal and neonatal development. Teratomas, particularly sacrococcygeal 
teratomas, are the most common neonatal tumor [1, 20, 21]. Neuroblastoma is the second most 
common neoplasm in neonates and the leading cause of malignancy in this group of patients. In 
order to decrease frequency, soft tissue tumors, central nervous system (CNS) tumors, leukemia, 
and renal tumors are the next most common tumor types recognized [1, 20, 21]. Table 1 pro-
vides a brief summary of the most frequently encountered neonatal tumors. Knowledge of the 
incidence, appearance, and typical locations of these lesions can provide important diagnostic 
Figure 1. Common neonatal tumors based on location.
Type Percentage
Extracranial teratoma 24–30%
Neuroblastoma 23–30%
Soft tissue tumors 8–12%
Leukemia 6–12%
CNS tumors 6–10%
Renal tumors 5–7%
Hepatic tumors 5%
Cardiopulmonary tumors <3%
Table 1. Distribution of commonly occurring neonatal tumors [1, 18, 20, 21].
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information. In particular, the location of the lesion gives a wealth of information regarding the 
differential diagnosis. The following discussions provide a location-based review of common 
neonatal tumors, which is intended to provide the clinician a basis to create a differential diagno-
sis to plan for management. Later, specific histologic diseases will be presented to allow tailoring 
of therapy.
4. Central nervous system
Primary central nervous system (CNS) neoplasms are the most common solid tumor in child-
hood and the leading cause of cancer death in this group of patients [22]. Fortunately, this 
is a rare entity with an estimated incidence of 5.57 cases per 100,000 children between the 
ages of 0 and 19 [23]. In neonates, CNS tumors are the fifth most common solid malignancy, 
which occur less frequently than lesions found in older children. Brain tumors in fetuses and 
neonates are unique in that they are often supratentorial, while lesions in older children are 
typically infratentorial [24]. The rarity of neonatal brain tumors and the absence of a national 
pediatric CNS cancer registry make it difficult to ascertain a true incidence [25].
In a retrospective review of 250 cases of perinatal brain tumors, Isaacs [24] found that the most 
common tumors were teratomas (29.6%), astrocytomas (18.8%), primitive neuroectodermal 
tumors (13.2%), and choroid plexus tumors (13.2%). Those children presenting with choroid 
plexus tumors, low-grade astrocytomas, and gangliogliomas had the best survival, while 
intracranial teratomas and neuroectodermal tumors exhibited the worst prognosis [24]. The 
5-year survival rate for neonatal brain tumors, regardless of treatment modality, is 23–36% 
[25]. The management of these patients includes surgical resection, chemotherapy, and irra-
diation, although any treatment decision should be coordinated through a multidisciplinary 
approach. Regardless of the histologic subtype and associated prognosis, the identification of 
a neonatal brain tumor is a devastating and life-altering experience for families.
5. Head and neck
Multiple conditions lead to the development of masses occurring in the head and neck of 
pediatric patients. The differential diagnosis is extensive and includes a variety of congeni-
tal, inflammatory, benign, and malignant lesions [26]. The vast majority of these lesions are 
benign. According to a comprehensive, 5-year review of 445 pediatric neck masses at Children’s 
Hospital of Philadelphia, the most frequent lesions were congenital in origin (55%), followed 
by inflammatory masses (27%), malignant neoplasms (11%), and benign neoplasms (3%) [27]. 
Inflammatory lesions likely account for the most common pediatric neck masses but often 
resolve with conservative therapy, obviating the need for biopsy or excision [26]. The inci-
dence and distribution of head and neck masses in the neonatal period are not as well defined.
The most common congenital head and neck lesions are branchial cleft, thyroglossal duct, 
and dermoid cysts. Although less common, vascular masses, lymphatic malformations, and 
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teratomas deserve special consideration secondary to the potential to cause detrimental effects 
on the developing fetus and newborn. Highly vascular lesions can lead to high-output cardiac 
failure and hydrops fetalis. Fluid accumulation in lymphatic malformations and the nearby tis-
sues can also lead to fetal hydrops. Mass effect and extrinsic compression from certain lesions 
have the potential to cause life-threatening airway obstruction as well as atypical development 
of adjacent structures. Cervical lymphatic malformations and cervical teratomas, two lesions 
responsible for these physiologic disturbances, will be discussed in greater detail later in this 
chapter.
Cervical vascular masses include congenital and infantile hemangiomas. An important dis-
tinction to make is that vascular malformations and congenital hemangiomas are present at 
birth, grow concurrently with the child, and do not involute. Vascular tumors develop in the 
neonatal period and demonstrate a proliferative phase followed by involution [28]. Infantile 
hemangiomas occur in up to 4–5% of newborns [29]. Infantile hemangiomas arise following 
birth, proliferate for a variable amount of time, and ultimately involute. In contrast, congeni-
tal hemangiomas proliferate in utero and are fully developed at birth. These masses can be 
subdivided into rapidly involuting and noninvoluting types. Congenital hemangiomas are 
rare, accounting for only 3% of all hemangiomas [30].
Malignant head and neck lesions are rarely diagnosed in neonates. Lymphomas are the most 
common head and neck malignancy in children, with 60% of these tumors being classified as 
non-Hodgkin’s lymphoma and the remaining 40% classified as Hodgkin’s lymphoma [31]. 
Excisional biopsy is usually necessary to provide adequate tissue to confirm the diagnosis. 
Following diagnosis, a multidisciplinary approach is recommended for appropriate staging 
and treatment [31]. Neuroblastoma is another malignancy that can be found in the head and 
neck of neonates. Typically, these are metastatic lesions as primary cervical neuroblastoma 
accounts for only 5% of neonatal neuroblastoma [32]. Some children may have a concomitant 
Horner’s syndrome secondary to compression of the cervical sympathetic chain. Treatment 
of neuroblastoma is also conducted via a multidisciplinary approach, with lesions diagnosed 
prenatally having a better prognosis than those identified following birth [32]. Other neonatal 
head and neck cancers include salivary gland malignancies, thyroid cancer, and nasopharyn-
geal carcinoma, each of which is exceedingly rare in this population.
6. Thoracic
The differential diagnosis of fetal and neonatal thoracic tumors can be narrowed signifi-
cantly with an understanding of their incidence and common locations. One useful method 
for organizing these tumors is to differentiate between mediastinal, pleural, and pulmonary 
neoplasms.
The anterior mediastinum includes the region between the sternum and pericardium below the 
thoracic inlet. The thymus, portions of the thyroid gland, and nodal tissue serve as potential 
sites for tumorigenesis. In a retrospective review of 534 fetuses and neonates diagnosed with 
teratomas, Isaacs [33] found that 2.6% of these masses occurred in the mediastinum. Teratomas 
that do occur in this region are usually located in the anterior mediastinum [34]. Sonographic 
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identification of calcifications can help differentiate mediastinal teratomas from congenital pul-
monary airway malformations and pulmonary sequestration [35]. Large mediastinal teratomas 
have the potential to cause lethal sequelae for the fetus and newborn. Polyhydramnios and pre-
term labor may develop from esophageal obstruction. High-output cardiac failure secondary 
to solid lesions with high vascularity can lead to fetal hydrops and intrauterine death. Perinatal 
decompensation and death are risks associated with intrathoracic airway obstruction. Although 
the thymus is included in the anterior mediastinum, thymomas are exceptionally rare in chil-
dren, with most of the published cases being limited to case reports and retrospective reviews. 
Thyroid neoplasms and lymphoma are also extremely rare in this group of patients.
The middle mediastinum encompasses the heart and pericardium, great vessels, tracheal 
bifurcation, and phrenic nerves. Primary cardiac tumors are very uncommon in the fetus and 
neonate [36]. Of the primary cardiac tumors that occur in these patients, nearly all of them 
are histologically benign [37, 38]. Rhabdomyomas account for the majority of these lesions 
[36–38]. Fibromas, myxomas, and teratomas represent additional benign cardiac lesions with 
rare occurrence. Pericardial-based teratomas are also exceedingly rare. Based on their size and 
location, middle mediastinal tumors can have a number of detrimental physiologic effects. 
Dysrhythmias, impairment of cardiac function, and great vessel compression may result in 
fetal or neonatal demise without timely intervention.
The posterior mediastinum is bound by the pericardium and thoracic vertebrae and extends 
from the sternal notch inferiorly to the diaphragm. The esophagus, descending thoracic 
aorta, azygos veins, thoracic duct, and neural tissue are the key components of this region. 
Nearly all of the tumors arising in the posterior mediastinum in children are neurogenic in 
origin. Neurogenic tumors are named according to the type of neural tissue from which they 
originate. Neoplasms that arise from the sympathetic chain reflect a continuum of cellular 
differentiation and maturation [39]. Ganglioneuromas are benign, fully differentiated, and 
arise from mature Schwann and ganglion cells. These are the most common posterior medi-
astinal masses in children [39]. Ganglioneuroblastomas are malignant tumors of intermedi-
ate differentiation and contain both mature and immature elements of ganglion cells [39]. 
Neuroblastomas are also malignant tumors that are derived from immature, undifferentiated 
ganglion cells [39]. Neuroblastoma is the most common malignancy and second most com-
mon tumor in neonates, with approximately 5% arising in the posterior mediastinum [32]. 
Additional tumors include neurofibroma, neurilemoma, neurosarcoma, and paraganglioma, 
all of which are uncommon in neonates.
Pulmonary lesions diagnosed prenatally or in the newborn are rarely true neoplasms. The 
most commonly identified abnormalities are congenital pulmonary malformations, intra- and 
extralobar pulmonary sequestrations, and congenital lobar emphysema. Pleuropulmonary 
blastoma is a very rare, aggressive pulmonary malignancy. Although uncommon, it is the 
primary pulmonary malignancy presenting in childhood with up to 94% of cases being diag-
nosed in children 6 years of age and younger [40]. Type I and II pleuropulmonary blastomas 
possess cystic components, which can lead to misdiagnosis as benign lesions. Since pleuro-
pulmonary blastoma is rare and over 90% of pulmonary cystic lesions in children are benign, 
surveillance may be an appropriate strategy with the knowledge that the emergence of solid 
components in the lesion warrants surgical resection [40].
Neonatal Tumors
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7. Abdominal/retroperitoneal/pelvic
Masses discovered in the neonatal abdominal cavity, retroperitoneum, and pelvis represent a 
very diverse group of pathologies as would be expected based on the tissue types and organs 
in this region. These lesions range from small incidentally discovered masses to those occupy-
ing an entire body cavity, from benign to malignant and from purely cystic to solid neoplasms 
[41]. Hepatic lesions are the most common intra-abdominal neonatal tumors, while neuro-
blastoma and teratoma are the most common retroperitoneal and pelvic masses, respectively.
Hepatic tumors encompass a variety of benign and malignant lesions, representing only 5% 
of neonatal tumors. Most neonatal liver tumors are benign and discovered as an asymptom-
atic abdominal mass or identified on prenatal imaging [5]. In a retrospective review of 194 
cases of fetal and neonatal hepatic tumors, Isaacs [42] identified hemangioma (60.3%), mes-
enchymal hamartoma (23.2%), and hepatoblastoma (16.5%) as the three primary tumor types. 
Hepatoblastoma represents the most common primary hepatic malignancy in this patient 
population. Serum alpha-fetoprotein is elevated in nearly half of neonates with hepatoblas-
toma; however, serum levels may remain elevated for several months following birth in chil-
dren with benign hepatic masses or in the absence of hepatic masses [43]. Surgical resection 
is the primary treatment modality for hepatoblastoma with chemotherapy typically reserved 
for children with unresectable lesions or metastatic disease. Newborns presenting with con-
genital hepatoblastoma appear to have similar survival when compared to older children 
with similar stages of disease [43].
Renal tumors account for approximately 5–7% of neonatal tumors. Non-neoplastic patholo-
gies, such as hydronephrosis and renal cystic disease, are far more prevalent than true neo-
plasms, accounting for up to 40% of neonatal abdominal masses [44]. The most common 
neonatal renal neoplasm is congenital mesoblastic nephroma (CMN), followed in frequency 
by Wilms’ tumor, rhabdoid tumor, and clear cell sarcoma [44]. Juxtarenal masses are also part 
of the differential diagnosis with neuroblastoma being the most common of these lesions.
Although prenatal ultrasound is widely used, it is estimated that only 15% of renal masses 
are diagnosed prenatally [45]. Of those lesions not diagnosed via fetal ultrasound, nearly 50% 
are identified during routine physical examination [45]. Mesoblastic nephroma is rarely diag-
nosed following the first 3 months of life, while it is uncommon for Wilms’ tumor to be diag-
nosed prior to 6 months of age [41]. Mesoblastic nephroma may be differentiated from other 
masses by the presence of a “ring sign” or anechoic circle surrounding the mass on sonog-
raphy [46]. The optimal treatment for neonatal renal masses is surgical resection. Similar to 
hepatic lesions, chemotherapy is reserved for malignant lesions that are unresectable or meta-
static at the time of diagnosis.
Teratomas are the most common neonatal tumors and the most prevalent pelvic neoplasms. 
In contrast, neonatal testicular tumors are rarely encountered in clinical practice. The tumors 
that do occur are usually testicular germ cell tumors such as teratomas and yolk sac tumors 
[47]. Diagnosis typically occurs after parents or clinicians palpate a testicular mass. Ultrasound 
examination distinguishes between intra- and extratesticular pathology. Yolk sac tumors are 
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the most common testicular malignancy in children, although most masses are benign. Serum 
alpha-fetoprotein (AFP) is a useful adjunct in the diagnosis of testicular tumors as it is elabo-
rated by nearly 90% of yolk sac tumors in childhood [48]. However, measuring AFP levels is 
less reliable in newborns as they can physiologically remain elevated for up to 1 year after 
birth in the absence of underlying pathology. Since most of these lesions are benign, some 
tumors can be excised with a testicle-sparing approach [49]. In the event that a malignancy is 
identified on intraoperative frozen section, radical orchiectomy is required.
Ovarian enlargement can result from a variety of pathologies including ovarian cysts, ovarian 
torsion, and benign and malignant neoplasms [50]. Fortunately, true neonatal ovarian masses 
are infrequently seen in practice. Many lesions are identified on prenatal imaging, although 
some children present with palpable abdominal or groin masses, endocrine abnormalities, or 
ambiguous genitalia and congenital anomalies [50]. The majority of fetal and neonatal ovar-
ian masses are cystic in nature. Management of ovarian cysts includes observation for simple 
lesions and surgical excision for larger, more complex lesions [41]. Preservation of functional 
ovarian parenchyma is the foundation of management.
8. Extremities and soft tissue
Soft tissue tumors comprise a heterogeneous group of benign and malignant neoplasms that 
represent 8–12% of neonatal tumors [1, 20, 21]. Soft tissue tumors are a rare entity in neonates, 
and the true incidence is unknown. There are a wide variety of benign tumors, including vas-
cular malformations, lipomas, lipoblastomas, and fibroblastic tumors.
Head and neck hemangiomas are the most common benign soft tissue tumors in neonates. 
Lipomas consist of a group of widely distributed fatty tumors that are composed of mature 
adipocytes with a histologic appearance identical to normal fat [51]. Lipomas are classified 
based on their depth, with superficial lesions being much more common than deep lesions, 
which are located beneath the superficial fascia [51]. Lipoblastomas are rare, benign, rap-
idly growing tumors that arise from embryonic white fat and typically occur on the trunk 
and limbs [52]. The treatment of lipomas and lipoblastomas is usually complete excision, 
although the extent of resection should take functional and cosmetic outcomes into consid-
eration. Fibroblastic and myofibroblastic tumors of intermediate prognosis represent benign 
lesions that display locally aggressive behavior with little to no propensity to metastasize 
[53]. Surgical resection remains the mainstay of treatment, yet a multidisciplinary approach is 
often necessary as radical resection of large, invasive lesions can lead to significant disfigure-
ment and disability [53].
In infants, rhabdomyosarcoma (32.8%) is the most common malignant soft tissue tumor, fol-
lowed in frequency by infantile fibrosarcoma (24.5%) and rhabdoid tumors (14.2%) [53]. Overall, 
malignant soft tissue tumors are rare in neonates. Rhabdoid tumors represent rare, aggressive 
malignancies that typically occur not only in the kidney and brain but can also be found in 
various soft tissue locations [54]. These tumors are relatively chemoresistant, demonstrate early 
tumor recurrence following surgical resection, and portend an overall poor prognosis [54].
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9. Birth considerations
Certain neonatal tumors warrant special consideration regarding fetal delivery and perinatal 
management. Neoplasms that compromise the fetal airway represent an immediate threat 
to the neonatal airway, with the potential for hypoxia, ischemic brain injury, and death 
[55]. Cervical teratomas, cervical lymphatic malformations, and cervical hemangiomas are 
the most common neoplasms with the propensity to cause extrinsic airway compression in 
the neck. Mediastinal tumors that compress the great vessels or intrathoracic trachea also 
demand specialized pre- and postnatal care. Large tumors, particularly sacrococcygeal tera-
tomas, merit consideration for Cesarean or early delivery as a method to avoid intrauterine 
or perinatal complications.
Prior to the development of the ex utero intrapartum treatment (EXIT) procedure, case reports 
described managing obstructing cervical masses with bronchoscopy and intubation prior to 
division of the umbilical cord [56]. The operation on placental support (OOPS) procedure 
involved Cesarean delivery of the head and thorax in order to perform endotracheal intu-
bation [57]. Inhaled isoflurane anesthesia was administered in hopes of minimizing uterine 
contractions in an effort to preserve fetoplacental circulation and prevent placental abruption 
[57]. These early procedures were felt to provide inadequate tocolysis and/or reduce the uter-
ine volume through fetal delivery, both of which result in uterine contraction and interrup-
tion of uteroplacental gas exchange [58].
Currently, the EXIT procedure offers a more comprehensive management approach to fetal 
and neonatal airway obstruction. The procedure also has application in the treatment of pul-
monary and mediastinal masses leading to airway obstruction or other physiologic derange-
ments. The EXIT procedure [59] entails intubating the mother and administering deep 
inhalational anesthesia with high-dose (2–3%) isoflurane. Anesthetic alone provides adequate 
uterine relaxation in many cases, but bolus doses of terbutaline or nitroglycerin can be given 
when necessary. Prior to performing hysterotomy, ultrasound is used to identify the location 
of the fetus and placenta. Following hysterotomy, the head and thorax of the fetus are deliv-
ered, allowing for multiple procedures to be performed, including bronchoscopy, orotracheal 
intubation, tracheostomy, mass excision, and ECMO cannulation. Fetoplacental circulation is 
preserved during the procedure and mitigates the possibility of hypoxia and brain ischemia. 
Once the airway is secured, the umbilical cord is divided, and Pitocin is administered, while 
the concentration of inhalational anesthetic is decreased to low levels or discontinued. The 
remainder of the procedure proceeds as would be expected from a routine Cesarean section.
Mediastinal tumors of appropriate size and location have the potential to cause fetal and 
neonatal demise through several mechanisms. One potential presentation is fetal airway and 
esophageal obstruction leading to polyhydramnios and preterm labor [60]. A second presen-
tation is great vessel compression with resulting nonimmune fetal hydrops and fetal demise 
[60]. Several successful management strategies have been reported. One strategy involves 
aspiration of the cystic component of mediastinal teratomas for size reduction and allevia-
tion of fetal hydrops until delivery and definitive management [61]. Serial amniocenteses to 
reduce uterine volume followed by neonatal resection have also been reported [60, 62–64]. 
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The EXIT procedure also serves as a useful adjunct in transitioning these children from intra-
uterine life to definitive airway control, ECMO cannulation, or surgical resection.
10. Common specific lesions
10.1. Teratomas
Teratomas are the most common neonatal tumors, accounting for up to 30% of these lesions 
in some series [1, 20, 21]. Teratomas typically occur in the midline, spanning a variety of loca-
tions from the pineal gland to the coccyx [34]. The distribution of these tumors is explained 
by the fact that they arise from pluripotent germ cells that arrest in abnormal locations dur-
ing embryologic migration [30]. Persistent division by these aberrant nests of cells results in 
tumors of varying size in diverse locations.
These neoplasms include all three germ cell layers, endoderm, mesoderm, and ectoderm. 
Most tumors are benign and can be classified as mature or immature based on their histologic 
appearance. Elements of the ectoderm, particularly neural tissue, are a dominant feature of 
immature fetal and neonatal teratomas [65, 66]. Mature and immature teratomas also contain 
mesenchymal components, including smooth muscle, cartilage, fat, and bone. Endodermal 
features such as respiratory and gastrointestinal epithelium are much less common [33, 65, 66]. 
Sacrococcygeal teratomas are the most common type of these tumors, followed in frequency 
by intracranial, cervical, palatal and nasopharyngeal, cardiac, gastric, and mediastinal terato-
mas [33]. Survival rates vary considerably by location, with intracranial teratomas (11%) hav-
ing the lowest survival and gastric teratomas (100%) demonstrating the best prognosis [33].
Sacrococcygeal teratomas represent 40–60% of teratomas and demonstrate a 3 to 1 female 
to male distribution [33, 67]. The estimated incidence is 1 in every 35,000 live births [68]. In 
countries where prenatal ultrasound is ubiquitous, many lesions are diagnosed in utero. In 
the absence of prenatal diagnosis, the classic presentation is that of a newborn with an evident 
mass on physical examination. Diagnosis of purely pelvic teratomas is frequently delayed [69]. 
Children in this category may develop urinary retention, constipation, a palpable abdominal 
mass, or failure to thrive. MRI serves as a useful adjunct to ultrasound in determining the 
degree of intrapelvic extension. In 1973, Altman et al. [69] developed a  location-based clas-
sification system for sacrococcygeal teratoma. Type I tumors are mainly external (sacrococ-
cygeal) with minimal presacral component. Type II tumors exhibit an  external component 
on presentation but have a substantial intrapelvic component. Type III tumor indicates a 
tumor with minimal external component with the majority of the mass located intrapelvic 
and extending into the abdomen. Type IV tumors are found entirely in the presacral space 
without any external component. Accurate classification is critical to parental counseling and 
appropriate operative planning.
Large sacrococcygeal teratomas represent a challenging diagnosis due to their potential to 
cause perinatal complications as well as unpredictable growth patterns [70]. Potential com-
plications associated with these tumors are numerous, consisting of premature labor from 
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polyhydramnios or increased intrauterine volume, tumor rupture, labor dystocia, hemor-
rhage, maternal mirror syndrome, and fetal hydrops secondary to high-output cardiac failure 
in highly vascular lesions [70]. Prenatally diagnosed sacrococcygeal teratomas should undergo 
frequent surveillance to monitor for rapidity of growth and development of the aforemen-
tioned complications [63]. For tumors that demonstrate a predominantly solid component 
with high vascularity, open fetal surgery may be necessary for tumor debulking to prevent 
high-output cardiac failure and fetal hydrops [71]. Similar to the management options for 
mediastinal teratomas, cyst aspiration and serial amniocenteses are beneficial interventions 
in appropriately selected patients [63, 64]. Cesarean delivery should be considered in larger 
lesions to prevent labor dystocia, tumor rupture, and hemorrhage.
En bloc resection of the tumor and coccyx is the primary treatment modality for sacrococ-
cygeal teratoma. Failure to remove the coccyx and gross tumor spillage appear to have the 
highest association with recurrence [72]. The presence of microscopically positive margins 
necessitates routine surveillance in the absence of yolk sac tumor elements on final pathology, 
while histologic confirmation of yolk sac tumor components warrants adjuvant chemotherapy 
[72]. The age at diagnosis correlates with the presence of underlying malignancy and overall 
survival. Approximately 10% of neonatal sacrococcygeal teratomas contain a yolk sac tumor 
with the incidence of a concurrent malignancy increasing with age [33]. The outcome of fetuses 
diagnosed with sacrococcygeal teratoma is worse than those diagnosed in neonates. The esti-
mated mortality for prenatally diagnosed lesions ranges from 33 to 50% and approaches 100% 
when fetal hydrops is present [33, 63, 73]. Conversely, the survival for a newborn diagnosed 
with this disease approaches 90% following complete surgical excision [33, 63, 73].
10.2. Neuroblastoma
Neuroblastoma represents the second most common neonatal tumor, accounting for 22.5–30% 
of these neoplasms, and the most common congenital malignancy [1, 20, 21]. Neuroblastomas 
are derived from primitive neural crest cells, or neuroblasts, and can be identified in any location 
where sympathetic tissue exists [74, 75]. Nearly 90% of fetal and neonatal cases of neuroblas-
toma occur in the adrenal gland compared to 35% in infants and older children [75, 76]. The next 
most common sites, in order to decrease frequency, are the retroperitoneum, posterior medias-
tinum, and neck [32]. The incidence of neuroblastoma is approximately 1 in 100,000 children, 
with a mean age of diagnosis of 18 months [77]. The incidence of neuroblastoma in neonates is 
not as well defined as tumors occur less commonly in this age group compared to older children.
Neuroblastoma is being diagnosed with increased frequency on prenatal ultrasound due 
to widespread use of fetal sonography and continued technological improvement [78]. In 
fact, there was once an interest in screening for neuroblastoma with prenatal ultrasound, 
but in general this practice has been abandoned as it only succeeded in identifying lesions 
that could otherwise be observed and did not identify the more aggressive lesions that most 
are interested in identifying early. The differential diagnosis of an adrenal lesion includes 
adrenal hemorrhage, adrenal abscess, adrenal cyst, and renal anomalies. Nearly all cases are 
diagnosed during the third trimester. Identification of a solid or cystic adrenal mass should 
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raise suspicion for the presence of an underlying neuroblastoma [78]. Postnatal MRI serves 
as useful to clarify the extent of disease and guide treatment options. Most mothers with a 
prenatal diagnosis of neuroblastoma are asymptomatic, although maternal hypertension and 
preeclampsia may occur due to elevated levels of catecholamines in maternal circulation [76]. 
In the absence of a prenatal diagnosis of neuroblastoma, presentation is variable and includes 
detection of a palpable abdominal mass, hepatomegaly, respiratory distress, and the presence 
of cutaneous nodules. Neuroblastomas are hormonally active tumors that secrete high levels 
of catecholamines and their by-products. The diagnosis can be further solidified by detection 
of these chemicals in a urine sample, although serum levels are not predictive of prognosis 
and do not dictate treatment.
Staging of neuroblastoma follows the International Neuroblastoma Staging System, which 
considers tumor location, nodal involvement, and the presence of metastases in assessing 
the burden of disease [79]. The majority of fetal and neonatal cases of neuroblastoma are 
stage I, stage II, and stage IV-S at the time of diagnosis [32, 76, 77]. Most tumors also demon-
strate favorable histology including N-myc non-amplification, stroma-rich appearance, and 
aneuploid DNA content [32, 76, 77]. Surgical resection is the principal treatment for local-
ized cases of neuroblastoma. In cases of unresectable disease, open or core needle biopsy 
provides valuable histologic information to help guide treatment decisions. Neonates with 
stage IV-S represent a particularly unique group of patients who have a localized tumor 
with metastases isolated to the liver, bone, and skin [79]. Despite the presence of meta-
static disease, these children have a favorable prognosis, and many tumors undergo spon-
taneous regression without specific treatment. Treatment options for stage IV-S include 
observation, surgical resection, and chemotherapy. Chemotherapy is also employed in the 
neoadjuvant setting for tumors that are initially deemed to be unresectable. Overall, the 
prognosis for fetal and neonatal neuroblastoma is excellent, with survival ranging from 70 
to 100% [32, 76, 77]. There have been favorable studies that have demonstrated success with 
observation with small lesions that likely represent neuroblastoma [80]. Moving forward, 
current staging is changing from a surgery-based staging toward image-defined risk cat-
egories with the majority of neonatal lesions falling into the low-risk categories. Therefore, 
we would recommend that these patients should be enrolled in current observation studies 
to document outcomes of this patient population.
10.3. Infantile hepatic hemangioma and mesenchymal hamartoma
Infantile hepatic hemangiomas are the most common primary liver tumors in newborns. 
Hemangiomas display a wide range of behavior, spanning from asymptomatic masses to 
those causing significant physiologic distress and potential demise [41]. Most lesions are 
diagnosed on prenatal imaging or found incidentally on physical examination. In some cases, 
the presence of cutaneous hemangiomas prompts evaluation for a concomitant hepatic mass 
[41]. Infantile hepatic hemangiomas are benign, vascular masses characterized by rapid post-
natal growth followed by involution in childhood [42]. For this reason, asymptomatic and 
smaller lesions can be observed for involution through serial ultrasonography. Conversely, 
some lesions develop severe arteriovenous shunting, which can lead to high-output cardiac 
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failure, fetal hydrops, and death. Other masses lead to Kasabach-Merritt syndrome, which can 
cause consumptive coagulopathy, thrombocytopenia, and hemolytic anemia [81]. Surgical 
excision is an effective management for localized lesions in children without severe physi-
ologic derangement. Selective hepatic arterial embolization can be used to induce preopera-
tive tumor shrinkage and in cases of refractory coagulopathy [82].
Mesenchymal hamartomas are the second most common hepatic tumor in newborns. These 
lesions are congenital malformations that contain elements of normal hepatic parenchyma 
including mesenchyme, portal venous branches, bile ducts, hepatocytes, and cysts of varying 
size [41]. Hamartomas are benign masses that display several chromosomal abnormalities 
[83]. Similar to hemangiomas, hamartomas are typically identified on prenatal imaging or 
found as an asymptomatic mass on physical examination. Approximately 75% are found in 
the right hepatic lobe with the rest involving the left lobe or both lobes [84]. Although these are 
histologically benign tumors, some lesions demonstrate rapid growth and result in significant 
physiologic disturbance. Tumors abutting the diaphragm can cause significant respiratory 
compromise. Compression of intra-abdominal vascular structures may lead to nonimmune 
fetal hydrops and fetal demise. Complete surgical excision is the optimal management for 
children with hepatic mesenchymal hamartomas. In tumors with large cystic components, 
fetal aspiration has been reported to mitigate detrimental fetal and obstetric sequelae [85].
10.4. Ovarian cysts
Ovarian cysts are the most common masses identified in neonatal girls and are nearly always 
benign. The etiology of ovarian cysts is not completely understood, but hormonal stimulation 
is felt to be responsible for this disease process [86]. In 1975, Valenti et al. [87] reported the first 
case of a prenatally diagnosed ovarian cyst. With improvement in ultrasonography, ovarian 
cysts are being identified with increasing frequency on prenatal imaging. Ultrasound provides 
vital information about size, location, wall characteristics, and vascularity [41]. However, many 
lesions are asymptomatic and would not be identified if not for routine fetal ultrasound [88].
Treatment of ovarian cysts hinges upon the risk of complications and the ability to differentiate 
between truly benign cysts and other ovarian neoplasms [89]. The most common complication 
encountered is ovarian torsion with subsequent loss of the affected ovary [86, 89]. Many cases 
of ovarian torsion occur prenatally, precluding the ability to intervene in an effort for ovarian 
preservation. Doppler evaluation is an unreliable measure of torsion in this patient popula-
tion secondary to vessel size and the fact that normal flow does not exclude the diagnosis [86]. 
Fetal cyst aspiration is one management strategy used to mitigate the risk of in utero torsion, 
but there is no agreed upon size cutoff to determine when this measure should be employed.
Simple cysts less than 4–5 cm in size can be observed for spontaneous regression with serial 
ultrasonography [41, 86, 88, 89]. Cysts larger than 4–5 cm are candidates for cyst aspiration 
or surgical intervention given a higher potential for ovarian torsion [41, 86, 88, 89]. Complex 
ovarian cysts, cysts that fail to regress spontaneously, cysts that recur following aspiration, 
and those that are symptomatic should be removed surgically [89]. Preservation of ovarian 
parenchyma is the hallmark of surgery for ovarian cysts. Options for surgical management 
include cyst unroofing, partial or total cystectomy, and oophorectomy. In cases of ovarian 
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torsion, the macroscopic appearance of the ovary does not necessarily correlate with the 
degree of parenchymal damage [88]. Pathologic evaluation of a portion of the cyst wall is 
recommended; however, the presence of an underlying malignancy is exceedingly rare.
10.5. Cervical lymphatic malformations
Lymphatic malformations are characterized by localized collections of malformed lymphatic 
channels that occur most commonly in the head and neck [90]. Lymphatic malformations typ-
ically occur in the posterior neck and are often associated with karyotypic abnormalities [91]. 
Other common locations are the trunk and extremities, the thoracic cavity, and the abdomi-
nal cavity. Traditionally, lymphatic malformations have been assigned to different categories 
based on histologic appearance: cavernous lymphangiomas, capillary lymphangiomas, and 
cystic hygroma [90]. However, the histologic classification does not seem to correlate with 
clinical behavior or response to therapy [90]. These masses follow a variable clinical course, 
with prenatally diagnosed lesions having a worse prognosis than those identified following 
birth [91].
Lymphatic malformations typically grow proportionally with the growth of the child, 
with rapid enlargement occurring as the result of trauma, hemorrhage, or infection [91]. 
Spontaneous infection occurs in approximately 7–30% of these masses [92]. The size and loca-
tion of a given lymphatic malformation are predictive of potential adverse consequences to 
the developing child. Head and neck lesions can lead to fetal esophageal obstruction, result-
ing in polyhydramnios and preterm labor. A more serious complication is the potential for 
neonatal airway obstruction and rapid demise following birth. The EXIT procedure [56] 
offers a comprehensive management strategy to establish a definitive airway while main-
taining fetoplacental circulation. However, if the lesion is soft and away from the midline, 
such fetuses may not require EXIT as obtaining an airway may not be difficult. Intrathoracic 
lymphatic malformations also have the potential to cause airway obstruction. Compression of 
the great vessels in the thorax and abdomen can cause high-output cardiac failure, hydrops 
fetalis, and fetal demise.
Many treatment modalities exist for the management of lymphatic malformations. In general, 
asymptomatic lesions can be observed for some time as many of these lesions will resolve 
without intervention. In those lesions that are large, growing, or symptomatic, therapeutic 
maneuvers include sclerotherapy and surgery. Prior to pursuing these therapies, the extent 
of the tumor and association with surrounding structures must be determined [91]. Nerves 
and major vessels should be preserved [90]. More complex and invasive lesions may require 
multiple, staged operations to achieve complete resection [90, 91]. Tumors that undergo com-
plete macroscopic excision show the lowest recurrence rates but still return in 17% of cases 
[93]. Recurrences occur in up to 100% of cases following aspiration and in 40% of masses that 
are incompletely excised [93]. The estimated recurrence rate following injection of sclerosing 
agents, such as sodium tetradecanol, bleomycin, and OK-432, ranges from 50 to 100% [91, 93]. 
Aspiration does play a role in emergent cases to decrease the mass effect of the tumor and 
establish an airway [90]. In small, asymptomatic lesions, a period of surveillance to monitor 
for spontaneous regression may also be pursued [90].
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10.6. Rhabdomyosarcoma
Soft tissue tumors account for 8–12% of neonatal tumors [1, 20, 21]. Rhabdomyosarcoma 
is the most common malignant soft tissue tumor in children, representing one third of 
these masses in infants and nearly half of soft tissue tumors found in older children [53]. 
Rhabdomyosarcoma is an aggressive, embryonal tumor of childhood marked by high-grade 
histology, local invasiveness, and a propensity to metastasize [53]. There are two main his-
tologic subtypes: embryonal rhabdomyosarcoma accounts for nearly 70% of all cases and 
portends a better prognosis and alveolar rhabdomyosarcoma which is characterized by 
numerous chromosomal translocations and has a worse overall outcome [94]. As mesenchy-
mal tumors that arise from skeletal muscle, rhabdomyosarcoma can occur in many locations 
throughout the body. The most common sites of occurrence are the head and neck followed 
by the genitourinary system and extremities [53]. Neonatal cases of rhabdomyosarcoma are 
rare. Male gender, Caucasian race, embryonal subtype, and undifferentiated histology are the 
predominant characteristics in neonates [95].
Rhabdomyosarcoma may be identified on prenatal imaging but more commonly presents as 
an identifiable mass following birth. The differential diagnosis is broad and includes many 
benign and malignant soft tissue tumors. Lymphatic involvement and metastatic disease are 
present in nearly 20% of cases at presentation [53]. The most common sites of metastasis are 
the lung, bone marrow, and bone. Neonatal cases of alveolar rhabdomyosarcoma may pres-
ent with brain metastases and subcutaneous nodules [96]. Biopsy of the primary lesion is 
recommended for diagnostic purposes and to determine tumor biology to guide treatment. 
However, one should proceed with complete excision of smaller lesions (<5 cm) if this can be 
performed with clear margins and without injury to surrounding structures. Larger or diffi-
cult to excise lesions should have an incisional biopsy with a sufficient tissue sample to allow 
for all necessary studies (1 cm3). Following diagnosis, tumors require staging with CT or MRI 
of the primary lesion, imaging of the chest, bone marrow aspiration, and bone marrow biopsy.
Treatment of neonatal rhabdomyosarcomas should be undertaken in a multidisciplinary 
fashion. Therapy is multimodal and includes systemic chemotherapy for metastatic disease 
and surgical resection and radiation for local disease. Complete surgical resection may not 
always be feasible, and age at diagnosis dictates the ability to give chemotherapy and radia-
tion. Age is an independent prognostic factor with children less than 1 year of age having a 
worse overall prognosis than children between the ages of 1 and 10 [97, 98]. In the Intergroup 
Rhabdomyosarcoma Study, Lobe et al. [95] found that only 49% of 14 newborns diagnosed 
with rhabdomyosarcoma were alive at 3 years.
10.7. Congenital mesoblastic nephroma
Congenital mesoblastic nephroma is the most common renal tumor occurring in neonates and 
during the first 3 months of life [45]. In a retrospective review of 210 renal tumors in fetuses 
and infants less than 2 months of age, Isaacs [44] found that the four most common renal 
neoplasms were congenital mesoblastic nephroma (66%), Wilms’ tumor (20%), rhabdoid 
tumor of the kidney (11%), and clear cell sarcoma of the kidney (3%). Congenital mesoblastic 
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nephroma demonstrates a slight male predominance with a male to female ratio of 1.5 to 1 
[45]. The most common presentations of mesoblastic nephroma are prenatal identification 
on fetal ultrasound, polyhydramnios, and palpation of an abdominal mass following birth. 
Sonographically, the presence of an anechoic circle or “ring sign” surrounding the mass may 
help differentiate congenital mesoblastic nephroma from other renal neoplasms [46]. These 
tumors typically demonstrate benign behavior; however, in addition to polyhydramnios, 
some masses may be complicated by hypertension; respiratory compromise; circulatory com-
promise from large, space-occupying lesions; and fetal hydrops [44].
Congenital mesoblastic nephroma (CMN) is a benign neoplasm that is characterized by leio-
myomatous histology with bundles of spindle cells, rare mitoses, and lack of necrosis [99]. 
The tumor can be further subdivided into classic and cellular subtypes based on histological 
appearance. Patients with the cellular subtype of CMN tend to have larger tumor burdens and 
older age of presentation [99]. Additionally, many cellular mesoblastic nephromas are cystic in 
nature, which may lead to increased risk of rupture and higher rates of recurrence [99]. Radical 
nephrectomy is the mainstay of treatment for a neonate diagnosed with CMN. Patients with 
the classic subtype of CMN are typically cured with surgical excision alone, while aggres-
sive tumors, which are often of the cellular subtype, may require adjuvant chemotherapy. 
Recurrence occurs in 5% of patients, while metastases are present in 2% of cases [44]. The over-
all survival for a patient diagnosed with congenital mesoblastic nephroma is 95–98% [99, 100].
11. Chemotherapy and irradiation
One of the greatest challenges in pediatric oncology is determining the appropriate dosing 
regimen for chemotherapeutic agents in young children [101]. Multiple factors influence the 
pharmacology of chemotherapeutic drugs in the newborn, including changes in blood flow, 
hepatic and renal development, and alterations in the amount of body composition attributed 
to fat and water [101]. Body surface area dosing is the most commonly employed dosing 
method in the pediatric setting, but there are inconsistencies in the cutoffs and magnitude 
for dose reductions [101]. Administration of chemotherapy in newborns should always take 
place under the guidance of a pediatric oncologist.
Radiation therapy is also very challenging in the pediatric patient population. Although 
radiation therapy has been successful in the treatment of many pediatric cancers, concerns 
remain about long-term side effects [102]. Growth and development failure is a primary con-
cern for children who receive radiation therapy [102]. Other late sequelae include neurocog-
nitive defects, infertility, cardiac and pulmonary abnormalities, gastrointestinal dysfunction, 
and secondary cancer development [102]. Over the last 35 years, the use of radiation therapy 
has declined in the treatment of many pediatric cancers, including Wilms’ tumor, neuroblas-
toma, ALL, and non-Hodgkin’s lymphoma [102]. The decision to use radiation therapy in the 
treatment of neonatal tumors should always include a discussion of the risks and benefits of 
therapy with a radiation oncologist. Of note for this patient population is the need to perform 
radiation under sedation as the drugs used in this treatment modality are under investigation 
as to potential long-term side effects.
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12. Conclusion
Neonatal tumors encompass an extremely diverse, heterogeneous group of neoplasms. 
Neonatal tumors demonstrate a broad spectrum of behaviors and outcomes with some lesions 
spontaneously regressing without treatment, while others are resistant to aggressive, multi-
modal therapy. The majority of lesions are benign, but histologic classification is not always 
predictive of clinical behavior or overall outcome. Treatment of neonatal tumors requires a 
clear understanding of the natural history of disease and the limitations of each treatment 
modality. The optimal management strategy incorporates the expertise of pediatricians, pedi-
atric surgeons, pediatric medical oncologists, and pediatric radiation oncologists.
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